Head-to-head evidence
Idecabtagene vicleucel vs SENL103
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Multiple Myeloma
Shared mechanism: BCMA · full Multiple Myeloma pipeline
Idecabtagene vicleucel
Marketed by Bristol-Myers Squibb
NCT03651128 · Phase 3 · completed
Randomized, open-label Phase 3 trial (n=386) demonstrating significant improvement in PFS vs standard regimens in relapsed/refractory multiple myeloma (NEJM 2023).
Next expected readout: May 2027 · NCT05393804 (registry estimate)
SENL103
Developed by Hebei Senlang Biotechnology
NCT06067581 · Phase 1 · status unknown
This is a small, uncontrolled, open-label Phase 1 dose-escalation study with no comparator arm, designed to find a safe dose of SENL103 CAR-T therapy in heavily pretreated myeloma patients. Efficacy is only a secondary measure and no results have been posted, so there is no evidence yet of a clinical effect.
Next expected readout: February 2028 · NCT07421856 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Idecabtagene vicleucel's landscape · SENL103's landscape